Evidence map›Paper›PMID 42746886›Full record

SynthesisImmunotherapy

Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis.

Abdulrahman F Al-Mashdali, Mujahid O Abdelraof, Rasha Kaddoura, Azza M Halfawi, Mohamed Elfatih M Yousif, Mohammed Abdulgayoom, Abdul Rashid Shah, Shehab F Mohamed

Abstract readSystematic ReviewMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Immunotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdulrahman F Al-MashdaliDepartment of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Mujahid O AbdelraofDepartment of Public and Environmental Health, Faculty of Medicine, Gezira University, Wad Madani, Sudan.
Rasha KaddouraDepartment of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Azza M HalfawiFaculty of Medicine, National Ribat University, Khartoum, Sudan.
Mohamed Elfatih M YousifFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Mohammed AbdulgayoomDepartment of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Abdul Rashid ShahDepartment of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Shehab F MohamedDepartment of Hematology and Bone Marrow Transplant, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence for chimeric antigen receptor T-cell (CAR-T) therapy in primary central nervous system lymphoma (PCNSL) remains limited and heterogeneous, with prior syntheses often combining primary and secondary CNS lymphoma.

methodsWe systematically searched PubMed, Scopus, and Web of Science through February 2026. The protocol was not registered in PROSPERO. Twenty-three reports were included: 15 studies in the quantitative synthesis (194 patients) and 8 reports in the qualitative synthesis (9 patients).

resultsThe pooled overall response rate was 68% (95% CI, 59-76; I

conclusionsCAR-T therapy demonstrates promising efficacy with manageable toxicity in PCNSL. Although early disease control is encouraging, long-term durability remains limited.

Indexed as

Central Nervous System NeoplasmsImmunotherapy, AdoptiveLymphomaReceptors, Chimeric AntigenT-LymphocytesCytokine Release SyndromeHumansReceptors, Antigen, T-CellTreatment OutcomeReceptors, Antigen, T-CellReceptors, Chimeric AntigenCAR T-cell therapyCRScytokine release syndromeICANSPCNSLPrimary CNS lymphoma

Identifiers

PMID42746886
PMCPMC13679336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.